专为乳腺病理设计的通用-专用协同模型,性能超越现有方法。
BRIGHT: A Collaborative Generalist-Specialist Foundation Model for Breast Pathology
- 采用通用与专科协同框架,融合跨器官知识与乳腺特异性特征。
- 在25项内部任务中全部达顶尖水平,11项外部验证中4项领先。
- 首个大规模乳腺病理基准,适合临床医生和病理研究者使用。
通用病理基础模型(PFM)在多器官数据上预训练后,在多种临床应用中展现出强大预测能力。然而,其在特定器官系统内完整覆盖临床关键任务的能力仍不明确,原因在于缺乏单一器官的大规模验证队列及能有效将普适组织形态学知识转化为专科级解读能力的定制训练范式。本研究提出BRIGHT,首个专为乳腺病理设计的基础模型,基于来自19家医院、超过4万名患者的51,000张乳腺全切片图像(WSI)进行训练。BRIGHT采用协作式通用-专科框架,以捕捉普遍性与器官特异性特征。为全面评估PFM在乳腺肿瘤学中的表现,我们构建了迄今最大的多中心队列用于下游任务开发与评估,涵盖10家医院超过25,000张WSI,覆盖25个不同临床任务,包括诊断、生物标志物预测、治疗反应与生存预测。大量实验表明,BRIGHT优于五种领先的通用型PFM,在25项内部验证任务中全部达到当前最优(SOTA),并在11项外部验证任务中4项领先,且热力图可解释性强。通过在大规模验证队列上评估,本研究不仅证实了BRIGHT在乳腺肿瘤学中的临床价值,也验证了协作式通用-专科范式的可行性,为特定器官系统基础模型的开发提供了可扩展模板。
原文摘要 · Abstract (English)
Generalist pathology foundation models (PFMs), pretrained on large-scale multi-organ datasets, have demonstrated remarkable predictive capabilities across diverse clinical applications. However, their proficiency on the full spectrum of clinically essential tasks within a specific organ system remains an open question due to the lack of large-scale validation cohorts for a single organ as well as the absence of a tailored training paradigm that can effectively translate broad histomorphological knowledge into the organ-specific expertise required for specialist-level interpretation. In this study, we propose BRIGHT, the first PFM specifically designed for breast pathology, trained on over 51,000 breast whole-slide images derived from a cohort of over 40,000 patients across 19 hospitals. BRIGHT employs a collaborative generalist-specialist framework to capture both universal and organ-specific features. To comprehensively evaluate the performance of PFMs on breast oncology, we curate the largest multi-institutional cohorts to date for downstream task development and evaluation, comprising over 25,000 WSIs across 10 hospitals. The validation cohorts cover the full spectrum of breast pathology across 25 distinct clinical tasks spanning diagnosis, biomarker prediction, treatment response and survival prediction. Extensive experiments demonstrate that BRIGHT outperforms five leading generalist PFMs, achieving state-of-the-art (SOTA) performance in 25 of 25 internal validation tasks and in 4 of 11 external validation tasks with excellent heatmap interpretability. By evaluating on large-scale validation cohorts, this study not only demonstrates BRIGHT's clinical utility in breast oncology but also validates a collaborative generalist-specialist paradigm, providing a scalable template for developing PFMs on a specific organ system, accelerating the translation of foundation models into ...
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。